{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:12:54Z","timestamp":1781831574047,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11033-019-04715-9","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T06:14:54Z","timestamp":1551852894000},"page":"2713-2720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-0283","authenticated-orcid":false,"given":"N.","family":"Sobhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pivetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ianza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bonazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zanconati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rizzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cortale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Confalonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"4715_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397\u2013408. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)67025-0","journal-title":"Lancet"},{"key":"4715_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of Pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"key":"4715_CR3","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","volume":"16","author":"R Hassan","year":"2010","unstructured":"Hassan R, Cohen SJ, Phillips M et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132\u20136138. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2275","journal-title":"Clin Cancer Res"},{"key":"4715_CR4","unstructured":"Gralla RJ, Hollen PJ, Liepa AM, et al (2003) Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the\u00a0lcss-Meso instrument [abstract 2496]\u00a0Proc Am Soc Clin Oncol 22"},{"key":"4715_CR5","first-page":"1007","volume":"61","author":"RA Leigh","year":"1982","unstructured":"Leigh RA, Webster I (1982) Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 61:1007\u20131009","journal-title":"S Afr Med J"},{"key":"4715_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0169-5002(00)00217-8","volume":"32","author":"BW Robinson","year":"2001","unstructured":"Robinson BW, Robinson C, Lake RA (2001) Localised spontaneous regression in mesothelioma\u2014possible immunological mechanism. Lung Cancer 32:197\u2013201","journal-title":"Lung Cancer"},{"key":"4715_CR7","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1158\/1078-0432.CCR-03-0239","volume":"10","author":"D Atanackovic","year":"2004","unstructured":"Atanackovic D, Block A, de Weerth A et al (2004) Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res 10:2600\u20132608","journal-title":"Clin Cancer Res"},{"key":"4715_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","volume":"4","author":"P DeLong","year":"2005","unstructured":"DeLong P, Carroll RG, Henry AC et al (2005) Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 4:342\u2013346","journal-title":"Cancer Biol Ther"},{"key":"4715_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humimm.2005.11.005","volume":"67","author":"F Meloni","year":"2006","unstructured":"Meloni F, Morosini M, Solari N et al (2006) Foxp3 expressing CD4+ CD25+ and CD8+ CD28\u2212 T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67:1\u201312. \n                    https:\/\/doi.org\/10.1016\/j.humimm.2005.11.005","journal-title":"Hum Immunol"},{"key":"4715_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027\u20131034","journal-title":"J Exp Med"},{"key":"4715_CR11","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.4049\/jimmunol.0901060","volume":"183","author":"AJ Currie","year":"2009","unstructured":"Currie AJ, Prosser A, McDonnell A et al (2009) Dual control of antitumor CD8 T cells through the programmed death-1\/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 183:7898\u20137908. \n                    https:\/\/doi.org\/10.4049\/jimmunol.0901060","journal-title":"J Immunol"},{"key":"4715_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Roden AC, Peikert T et al (2014) B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9:1036\u20131040. \n                    https:\/\/doi.org\/10.1097\/JTO.0000000000000177","journal-title":"J Thorac Oncol"},{"key":"4715_CR13","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J et al (2015) Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 10:e0121071. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0121071","journal-title":"PLoS ONE"},{"key":"4715_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","volume":"59","author":"N Yamada","year":"2010","unstructured":"Yamada N, Oizumi S, Kikuchi E et al (2010) CD8 + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 59:1543\u20131549. \n                    https:\/\/doi.org\/10.1007\/s00262-010-0881-6","journal-title":"Cancer Immunol Immunother"},{"key":"4715_CR15","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Nitadori J-I et al (2015) The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology 4:e1009285. \n                    https:\/\/doi.org\/10.1080\/2162402X.2015.1009285","journal-title":"Oncoimmunology"},{"key":"4715_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259\u2013271. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"4715_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","volume":"135","author":"M Anraku","year":"2008","unstructured":"Anraku M, Cunningham KS, Yun Z et al (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135:823\u2013829. \n                    https:\/\/doi.org\/10.1016\/j.jtcvs.2007.10.026","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4715_CR18","doi-asserted-by":"publisher","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","volume":"6","author":"K Kiyotani","year":"2017","unstructured":"Kiyotani K, Park J-H, Inoue H et al (2017) Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology 6:e1278330. \n                    https:\/\/doi.org\/10.1080\/2162402X.2016.1278330","journal-title":"Oncoimmunology"},{"key":"4715_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello G, Zago G, Lunardi F et al (2018) Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical\u2013pathological features and intratumor heterogeneity over time. Ann Oncol 29:1258\u20131265. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy086","journal-title":"Ann Oncol"},{"key":"4715_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-017-3927-8","volume":"17","author":"Y Asano","year":"2017","unstructured":"Asano Y, Kashiwagi S, Goto W et al (2017) Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. BMC Cancer 17:888. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3927-8","journal-title":"BMC Cancer"},{"key":"4715_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4048\/jbc.2013.16.1.32","volume":"16","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Seo J-Y, Ahn J-H et al (2013) Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 16:32. \n                    https:\/\/doi.org\/10.4048\/jbc.2013.16.1.32","journal-title":"J Breast Cancer"},{"key":"4715_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105\u2013113. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.7370","journal-title":"J Clin Oncol"},{"key":"4715_CR23","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.humpath.2011.12.013","volume":"43","author":"R Yamaguchi","year":"2012","unstructured":"Yamaguchi R, Tanaka M, Yano A et al (2012) Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 43:1688\u20131694. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2011.12.013","journal-title":"Hum Pathol"},{"key":"4715_CR24","doi-asserted-by":"publisher","first-page":"44288","DOI":"10.18632\/oncotarget.9988","volume":"7","author":"K Wang","year":"2016","unstructured":"Wang K, Xu J, Zhang T, Xue D (2016) Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: a meta-analysis. Oncotarget 7:44288\u201344298. \n                    https:\/\/doi.org\/10.18632\/oncotarget.9988","journal-title":"Oncotarget"},{"key":"4715_CR25","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode EL, Block MS, Kalli KR et al (2017) Dose-response association of CD8 tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3:e173290. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290","journal-title":"JAMA Oncol"},{"key":"4715_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. \n                    https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"4715_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.imlet.2010.09.022","volume":"134","author":"D Fanoni","year":"2011","unstructured":"Fanoni D, Tavecchio S, Recalcati S et al (2011) New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 134:157\u2013160. \n                    https:\/\/doi.org\/10.1016\/j.imlet.2010.09.022","journal-title":"Immunol Lett"},{"key":"4715_CR28","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.18632\/oncotarget.24075","volume":"9","author":"T Sakane","year":"2018","unstructured":"Sakane T, Murase T, Okuda K et al (2018) A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. Oncotarget 9:6993\u20137009. \n                    https:\/\/doi.org\/10.18632\/oncotarget.24075","journal-title":"Oncotarget"},{"key":"4715_CR29","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.2217\/fon-2017-0224","volume":"13","author":"N Sobhani","year":"2017","unstructured":"Sobhani N, Corona SP, Bonazza D et al (2017) Advances in systemic therapy for malignant mesothelioma: future perspectives. Future Oncol 13:2083\u20132101. \n                    https:\/\/doi.org\/10.2217\/fon-2017-0224","journal-title":"Future Oncol"},{"key":"4715_CR30","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan R, Thomas A, Alewine C et al (2016) Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 34:4171\u20134179. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.3672","journal-title":"J Clin Oncol"},{"key":"4715_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1556-0864(16)30330-6","volume":"11","author":"T Jahan","year":"2016","unstructured":"Jahan T, Hassan R, Alley E et al (2016) Deferred publication: mesothelioma 208O_PR CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial. J Thorac Oncol 11:4\u2013156. \n                    https:\/\/doi.org\/10.1016\/S1556-0864(16)30330-6","journal-title":"J Thorac Oncol"},{"key":"4715_CR32","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.021557498","volume":"98","author":"I Hellstrom","year":"2001","unstructured":"Hellstrom I, Ledbetter JA, Scholler N et al (2001) CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc Natl Acad Sci USA 98:6783\u20136788. \n                    https:\/\/doi.org\/10.1073\/pnas.021557498","journal-title":"Proc Natl Acad Sci USA"},{"key":"4715_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A et al (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18:623\u2013630. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30169-9","journal-title":"Lancet Oncol"},{"key":"4715_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF et al (2018) PD-1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038","journal-title":"J Thorac Oncol"},{"key":"4715_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","volume":"19","author":"DA Fennell","year":"2018","unstructured":"Fennell DA, Kirkpatrick E, Cozens K et al (2018) CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials 19:233. \n                    https:\/\/doi.org\/10.1186\/s13063-018-2602-y","journal-title":"Trials"},{"key":"4715_CR36","doi-asserted-by":"publisher","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","volume":"36","author":"A Desai","year":"2018","unstructured":"Desai A, Karrison T, Rose B et al (2018) Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol 36:8565\u20138565. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.8565","journal-title":"J Clin Oncol"},{"key":"4715_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","volume":"12","author":"B Thapa","year":"2017","unstructured":"Thapa B, Salcedo A, Lin X et al (2017) The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol 12:850\u2013859. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2017.02.013","journal-title":"J Thorac Oncol"},{"key":"4715_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","volume":"12","author":"S Lantuejoul","year":"2017","unstructured":"Lantuejoul S, Le Stang N, Damiola F et al (2017) PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better? J Thorac Oncol 12:778\u2013781. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2017.03.018","journal-title":"J Thorac Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-04715-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:08:38Z","timestamp":1583366918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-04715-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4715"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-04715-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"17 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent for publication was obtained from all authors of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}